Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acerus Pharmaceuticals Corporation (T:ASP)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 2486 Dunwin Dr
Tel: N/A
IR: See website
Key People
Ian O. Ihnatowycz
Independent Chairman of the Board
Edward Joseph Gudaitis
President, Chief Executive Officer, Director
Robert M. Motz
Chief Financial Officer
Tricia Symmes
Chief Operating Officer
Matthew Hawkins
Vice President - Legal Affairs, Corporate Secretary
Nathan Bryson
Vice President - Scientific Affairs
Rolf K. Reininghaus
Executive Director, Director
Business Overview
Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral, plant-derived 17-beta estradiol therapy for the relief of symptoms of menopause. The Company offers Natesto, which is the testosterone nasal gel in the United States for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The Company offers TEFINA, which is a low-dose nasal testosterone gel treatment in development for female sexual dysfunction. The Company focuses on TriVair Deposition/Dispersion System, which is a unit dose dry powder inhaler and nasal dispersion system.
Financial Overview
For the nine months ended 30 September 2019, Acerus Pharmaceuticals Corporation revenues decreased 39% to $3.3M. Net loss decreased 11% to $12.2M. Revenues reflect Canada segment decrease of 49% to $2.1M. Lower net loss reflects Selling and marketing decrease of 49% to $910K (expense), Foreign exchange (gain)/loss increase from $353K (expense) to $94K (income).
Employees: 29 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $24.18M as of Sep 30, 2019
Annual revenue (TTM): $7.02M as of Sep 30, 2019
EBITDA (TTM): -$14.11M as of Sep 30, 2019
Net annual income (TTM): -$22.80M as of Sep 30, 2019
Free cash flow (TTM): -$9.97M as of Sep 30, 2019
Net Debt Last Fiscal Year: $13.11M as of Sep 30, 2019
Shares outstanding: 261,225,290 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization